Lorus Therapeutics Inc. completed a $32.775 million public offering of units on June 11, 2003. The offering was made in Canada pursuant to a short form prospectus filed in each province and in the U.S. pursuant to applicable exemptions. The agent syndicate was led by Loewen, Ondaatje, McCutcheon Limited, and included Dundee Securities Corporation, Harris Partners and Haywood Securities. The offering included an agent over-allotment option that was exercised in full at the closing.
Lorus Therapeutics was represented by in-house counsel Shane Ellis, and assisted by Torys LLP with a team that included Vanessa Grant, Peter Walker and Kevin Andrade (corporate), Glen Johnson (Canadian securities) and Dan Miller (U.S. securities). Intellectual property advice was provided by Marusyk Miller & Swain LLP in Ottawa, with a team that included Randy Marusyk, Ariadni Athanassiadis, Sarah Dale-Harris, Katie Wang, Victor Choi, Mervyn Valadares and Sharon Griffin, and assisted by Charles Boulakia, Robin Coster and Nadine D'Aguiar of Torys.
The agents were represented by Stikeman Elliott LLP, with a team that included Jay Kellerman, Robert Mason and Mark Katz (corporate), Wesley Ng (biotechnology) Eugene Derényi (intellectual property) and David Glicksman (tax).
Lorus Therapeutics was represented by in-house counsel Shane Ellis, and assisted by Torys LLP with a team that included Vanessa Grant, Peter Walker and Kevin Andrade (corporate), Glen Johnson (Canadian securities) and Dan Miller (U.S. securities). Intellectual property advice was provided by Marusyk Miller & Swain LLP in Ottawa, with a team that included Randy Marusyk, Ariadni Athanassiadis, Sarah Dale-Harris, Katie Wang, Victor Choi, Mervyn Valadares and Sharon Griffin, and assisted by Charles Boulakia, Robin Coster and Nadine D'Aguiar of Torys.
The agents were represented by Stikeman Elliott LLP, with a team that included Jay Kellerman, Robert Mason and Mark Katz (corporate), Wesley Ng (biotechnology) Eugene Derényi (intellectual property) and David Glicksman (tax).
Lawyer(s)
Mark F. Katz